Prostatype Genomics AB (publ)

Stockholm Stock Exchange PROGEN.ST

Prostatype Genomics AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 40.95

Prostatype Genomics AB (publ) Price to Sales Ratio (P/S) is 40.95 on January 14, 2025, a -26.01% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Prostatype Genomics AB (publ) 52-week high Price to Sales Ratio (P/S) is 100.71 on August 13, 2024, which is 145.90% above the current Price to Sales Ratio (P/S).
  • Prostatype Genomics AB (publ) 52-week low Price to Sales Ratio (P/S) is 11.74 on June 17, 2024, which is -71.32% below the current Price to Sales Ratio (P/S).
  • Prostatype Genomics AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 36.01.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Stockholm Stock Exchange: PROGEN.ST

Prostatype Genomics AB (publ)

CEO Mr. Fredrik Rickman
IPO Date Nov. 3, 2020
Location Sweden
Headquarters Industrivägen 19
Employees 6
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.

Similar companies

SPRINT.ST

Sprint Bioscience AB (publ)

USD 0.14

1.34%

StockViz Staff

January 15, 2025

Any question? Send us an email